ASIAMEDIC LIMITED (505) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of ASIAMEDIC LIMITED S$0.02, price S$0.02, upside +29.4%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ASIAMEDIC LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 0.0090 SGD – 0.0270 SGD · fair‑value band 0.0202 SGD – 0.0238 SGD · the 0.0170 SGD price screens below the 0.0220 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow ASIAMEDIC in your weekly email
Every Wednesday you see whether ASIAMEDIC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AsiaMedic Limited provides healthcare services in Singapore.
Show more
AsiaMedic Limited provides healthcare services in Singapore. It offers diagnostic imaging and radiology services, such as magnetic resonance imaging, computed tomography, bone densitometry, ultrasound, mammography, and x-ray imaging services, as well as cardiovascular, musculoskeletal, ear, nose and throat, breast, body, and neuroradiology assessments to general practitioners, specialists, and hospitals; and positron emission tomography and computed tomography scans for cardiac and cancer imaging. The company also provides primary healthcare services; medical aesthetic services, including laser skin rejuvenation, non-surgical facelifts, dermal fillers, body contouring, and skincare solutions; medical arrangement, travel medical concierge, diagnostic scan, wellness, medical evacuation, and visa services; and pharmaceuticals and aesthetic products. In addition, it operates family clinics and a boutique aesthetic clinic. The company was incorporated in 1974 and is based in Singapore.
Stock analysis
ASIAMEDIC LIMITED (505) currently trades at 0.0170 SGD, while our model-based Fair Value estimate is 0.0220 SGD, implying the stock looks roughly 22.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 0.0500 SGD per share, and 19 of the 24 models we run sit above the 0.0170 SGD price.
Bear case: the Asset-Based group reads lowest at 0.0100 SGD, and 5 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.0202 SGD (bear) to 0.0238 SGD (bull), the price of 0.0170 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ASIAMEDIC LIMITED reported revenue of 35.2M SGD in FY2025 versus 18.3M SGD in FY2021, a compound +17.9%/yr. Reported net income was 2.0M SGD in FY2025, compounding +29.7%/yr from FY2021.
Key figures
Market cap 26.4M SGD (≈ $20.6M) · P/S ratio 0.75 · Net margin 5.7% · Return on equity 8.2% · Return on assets (EBIT) 2.3% · Operating margin 5.8% · Revenue (TTM) 35.3M SGD · Revenue growth (YoY) +17.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 29%, 505 screens cheaper than that median.
Fair Value models
Bear 0.0202 SGDFair Value 0.0220 SGDBull 0.0238 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+22.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−31% → 1%
⚠ Revenue per share shrinking 9.5%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −8.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 131 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+29.4% · Top 25%
Profitability
Return on equity (TTM)8.2% · Above median
Return on assets0.9% · Below median
Net margin (TTM)5.7% · Above median
Operating margin (TTM)5.8% · Below median
Growth and dividend
Revenue growth17.7% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ASIAMEDIC LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/505
Frequently asked questions
Is ASIAMEDIC LIMITED (505) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.0220 SGD versus a price of 0.0170 SGD, about +29% upside (undervalued).
What is the fair value of 505?
Our model-based fair value for ASIAMEDIC LIMITED is 0.0220 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.0170 SGD.
What is the quality score of 505?
ASIAMEDIC LIMITED has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ASIAMEDIC LIMITED (505)?
Our model-based price target is the fair value of 0.0220 SGD (as of Sep 27, 2026) from 24 valuation models. Cautious scenario 0.0202 SGD, optimistic scenario 0.0238 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the ASIAMEDIC LIMITED stock forecast for 2026?
Our models put fair value at 0.0220 SGD, about +29% upside versus a price of 0.0170 SGD (undervalued). Cautious scenario 0.0202 SGD, optimistic scenario 0.0238 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of ASIAMEDIC LIMITED (505)?
ASIAMEDIC LIMITED reported trailing-twelve-month revenue of about 35.3M SGD (latest available figure, as of Sep 27, 2026).
What growth is priced into ASIAMEDIC LIMITED (505)?
For today's price to be fair in a discounted-cash-flow model, ASIAMEDIC LIMITED would have to grow free cash flow by -6.7 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.2 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 505 use?
Our models discount ASIAMEDIC LIMITED at 8.3 %: a base by market capitalisation (nano), damped by beta 0.17, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ASIAMEDIC LIMITED that is -6.7 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has ASIAMEDIC LIMITED (505) delivered so far?
Over the past 5 years revenue at ASIAMEDIC LIMITED grew +18.2 % a year. The price currently implies -6.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ASIAMEDIC LIMITED (505) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into ASIAMEDIC LIMITED (-6.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ASIAMEDIC LIMITED (505)?
The free-cash-flow yield on the price is 6.26 %: that much free cash flow ASIAMEDIC LIMITED produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ASIAMEDIC LIMITED (505)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ASIAMEDIC LIMITED it is 0.0220 SGD per share (as of Sep 27, 2026), against a price of 0.0170 SGD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is ASIAMEDIC LIMITED stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 505 trades below its calculated fair value: price 0.0170 SGD, fair value 0.0220 SGD, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 505?
No. The price is what the market pays today (0.0170 SGD); the fair value is what the company's own numbers justify (0.0220 SGD). For ASIAMEDIC LIMITED the two are 0.0050 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is ASIAMEDIC LIMITED worth?
The market values ASIAMEDIC LIMITED at about 26.4M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.0170 SGD; our models calculate a fair value of 0.0220 SGD per share.
What do the bullish and bearish scenarios say about 505?
Our models span a range for ASIAMEDIC LIMITED: cautious scenario 0.0202 SGD, base 0.0220 SGD, optimistic 0.0238 SGD per share (as of Sep 27, 2026, price 0.0170 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ASIAMEDIC LIMITED (505)?
Balance-sheet figures for ASIAMEDIC LIMITED (as of Sep 27, 2026): return on equity 8.2%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 505 from its 52-week high?
ASIAMEDIC LIMITED trades at 0.0170 SGD, about 37% below its 52-week high of 0.0270 SGD and 6% above the low of 0.0160 SGD (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0220 SGD is for.
Which stocks are comparable to ASIAMEDIC LIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ASIAMEDIC LIMITED stock attractive at the current price?
The data as of Sep 27, 2026: price 0.0170 SGD, calculated fair value 0.0220 SGD (+29%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 505 calculated?
We run ASIAMEDIC LIMITED through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0220 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ASIAMEDIC LIMITED currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ASIAMEDIC LIMITED (505)?
The closing price on Sep 28, 2026 was 0.0170 SGD. Our model-based fair value is 0.0220 SGD, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ASIAMEDIC LIMITED right now?
The price is below even our cautious bear case (0.0202 SGD). The market is more pessimistic than our downside scenario. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of ASIAMEDIC LIMITED
How large is the market capitalisation of ASIAMEDIC LIMITED (505)?
The market capitalisation of ASIAMEDIC LIMITED is 26.4M SGD (≈ $20.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ASIAMEDIC LIMITED (505)?
The price-to-sales ratio of ASIAMEDIC LIMITED is 0.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ASIAMEDIC LIMITED (505)?
The net margin of ASIAMEDIC LIMITED is 5.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ASIAMEDIC LIMITED (505)?
The return on equity (ROE) of ASIAMEDIC LIMITED is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ASIAMEDIC LIMITED (505)?
On an EBIT basis the return on assets of ASIAMEDIC LIMITED is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ASIAMEDIC LIMITED (505)?
The operating margin of ASIAMEDIC LIMITED is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ASIAMEDIC LIMITED (505)?
Revenue at ASIAMEDIC LIMITED is growing +17.7% versus a year earlier (3y avg +23.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ASIAMEDIC LIMITED (505)?
Earnings per share at ASIAMEDIC LIMITED are growing +81.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch ASIAMEDIC LIMITED in the live analysis
One click puts ASIAMEDIC LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
